The tumor immune contexture of salivary duct carcinoma
Background Salivary duct carcinoma (SDC) is a rare and aggressive malignancy. Recently, biomarker studies found promising targetable alterations. In this study, we provide a descriptive analysis of tumor and immune biomarkers and survival associations. Methods We extracted clinical data and performe...
Saved in:
| Published in: | Head & neck Vol. 43; no. 4; pp. 1213 - 1219 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Hoboken, USA
John Wiley & Sons, Inc
01-04-2021
Wiley Subscription Services, Inc |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy. Recently, biomarker studies found promising targetable alterations. In this study, we provide a descriptive analysis of tumor and immune biomarkers and survival associations.
Methods
We extracted clinical data and performed immunohistochemistry for AR, AR‐V7, HER‐2, PD‐L1, LAG‐3, and tumor‐infiltrating immune cells.
Results
We included 17 patients. Age ranged from 42 to 85 years old; HER‐2 was overexpressed or amplified in 65%. AR was positive in 88% of patients, while AR‐V7 was positive in 13% by IHC. We found low scores of immune infiltration and a PD‐L1 expression in 53%. We found no clinically significant association between biomarkers and survival outcomes.
Conclusion
In this small series of SDC, biomarkers do not seem to correlate with disease biology, although they provide additional treatment options. SDC may harbor a different immune profile compared to other subtypes, with an indication of T‐cell dysfunction. |
|---|---|
| ISSN: | 1043-3074 1097-0347 |
| DOI: | 10.1002/hed.26587 |